Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study - Concepedia

Concepedia

Publication | Open Access

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

DOI Full Paper Access

220

Citations

12

References

2015

Year

Ian Landells, Colleen Marano, Ming-Chun Hsu, Shu Li, Yaowei Zhu, Lawrence F. Eichenfield, Peter H. Hoeger, Alan Menter, Amy S. Paller, Sandra Philipp,

Journal of the American Academy of Dermatology

Abstract

In this patient population (12-17 years), the standard ustekinumab dose provided response comparable to that in adults with no unexpected AEs through 1 year.

References

	Year	Citations

Page 1